A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Triple Negative Locally Advanced Non-resectable Breast Cancer|HR+, HER2-, Advanced Breast Cancer
DRUG: STAR0602|DRUG: Sacituzumab Govitecan (SG)
Phase 1 (Safety Run-In): Number of Participants with Dose Limiting Toxicites (DLTs), 21 days following the first dose of STAR0602 + Sacituzumab Govitecan|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Number of Participants with Adverse Events and Serious Adverse Events, Up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Percentage of participants with Overall Objective Tumor Responses (ORR), Proportion of participants who have a complete response (CR) or partial response (PR), Up to 3 years
Phase 1 and 2 (Safety Run-In and Cohort Expansion): Duration of Response (DOR), Up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Percentage of Participants with Disease Contral (DCR), Proportion of participants who have a complete response (CR) or partial response (PR) or stable disease (SD), Up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Progression Free Survival (PFS), Up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Overall Survival (OS), Up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Maximum Observed Concentration (Cmax) for STAR0602, Cycle 1 and Cycle 3 at predefined intervals (Cycle length = 21 days) up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Area Under the Concentration Curve (AUC) for STAR0602, Cycle 1 and Cycle 3 at predefined intervals (Cycle length = 21 days) up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Apparent Total Body Clearance (CL) for STAR0602, Cycle 1 and Cycle 3 at predefined intervals (Cycle length = 21 days) up to 3 years|Phase 1 and 2 (Safety Run-In and Cohort Expansion): Apparent Volume of Distribution (Vd) for STAR0602, Cycle 1 and Cycle 3 at predefined intervals (Cycle length = 21 days) up to 3 years
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.